Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial.

OBJECTIVE To assess the effectiveness of a multifaceted intervention to improve the management of glucocorticoid-induced osteoporosis (GIOP). METHODS Of 21 rheumatologists, 11 were randomly assigned to a 3-part intervention consisting of a lecture and discussion regarding optimal management of GIOP, a confidential doctor-specific audit regarding management of GIOP, and a reminder mailing including concise pharmacologic recommendations. The remaining 10 rheumatologists received no special education. Patients with rheumatoid arthritis (RA) taking oral glucocorticoids seen in the 2 months after the intervention were followed for 6 months. Medical records were assessed to determine the proportion undergoing bone mineral density testing or receiving pharmacologic interventions for GIOP during the 6 months before and 6 months after the intervention. RESULTS There were 373 patients with RA taking oral glucocorticoids whose records were assessed. Patients in both arms of the trial were similar with respect to age, sex, menopausal status, glucocorticoid dosage and duration, duration of RA, disease-modifying antirheumatic drug use, and the proportion with comorbid conditions. At baseline, there was no significant difference between the patients with respect to osteoporosis medication use (intervention 32% versus control 34%) or bone densitometry use (intervention 9% versus control 5%). After the intervention and a 6-month followup period, there were no differences in treatment (intervention 33% versus control 38%) or bone densitometry use (intervention 8% versus control 8%). Adjusting for patient and physician characteristics did not significantly change these results. CONCLUSION A multifaceted intervention for GIOP, including doctor education, practice audit, and treatment suggestions, had no significant benefit on testing or treatment by rheumatologists over a 6-month followup period. Other intervention approaches need to be tested.

[1]  J. Katz,et al.  Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. , 2002, Arthritis and rheumatism.

[2]  G. Haugeberg,et al.  Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. , 2002, Arthritis and rheumatism.

[3]  A. Localio,et al.  Adjustments for Center in Multicenter Studies: An Overview , 2001, Annals of Internal Medicine.

[4]  J. Allison,et al.  Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. , 2001, The Journal of rheumatology.

[5]  J. Gurwitz,et al.  Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. , 2001, Archives of internal medicine.

[6]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[7]  M. Hochberg,et al.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis , 2001 .

[8]  C. Cooper,et al.  Use of Oral Corticosteroids and Risk of Fractures , 2000 .

[9]  G. Haugeberg,et al.  Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. , 2000, Arthritis and rheumatism.

[10]  N. Lane,et al.  Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. , 1999, The American journal of medicine.

[11]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[12]  N. Freemantle,et al.  Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? , 1999, JAMA.

[13]  C. Cooper,et al.  A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update , 1998, Journal of internal medicine.

[14]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[15]  A D Oxman,et al.  No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[16]  C. Goldsmith,et al.  Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. , 1994, The Journal of rheumatology.

[17]  P. V. van Riel,et al.  Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis , 1993, Annals of Internal Medicine.

[18]  F. Wolfe,et al.  Fractures in rheumatoid arthritis: an evaluation of associated risk factors. , 1993, The Journal of rheumatology.

[19]  L. Melton,et al.  Fractures after rheumatoid arthritis. A population-based study. , 1984, Arthritis and rheumatism.